|PUBLICATIONS (Ranked by impact factor of the journal)|
Control of MT1-MMP Transport by Atypical PKC during Breast-Cancer Progression
Researchers report a co-up-regulation and colocalization of membrane type 1-matrix metalloproteinase (MT1-MMP) and atypical protein kinase C (PKC) iota in hormone receptor-negative breast tumors in association with a higher risk of metastasis. [Proc Natl Acad Sci USA]
MicroRNA-519a Is a Novel Oncomir Conferring Tamoxifen Resistance by Targeting a Network of Tumor-Suppressor Genes in ER+ Breast Cancer
Although the role of a few microRNAs (miRNAs) has been described in tamoxifen resistance at the single gene/target level, little is known about how concerted actions of miRNAs targeting biological networks contribute to resistance. Investigators identified the miRNA cluster, C19MC, which harbors around 50 mature miRNAs, to be upregulated in resistant cells, with miRNA-519a being the most highly upregulated. [J Pathol]
HS3ST2 Modulates Breast Cancer Cell Invasiveness via MAP Kinase- and Tcf4 (Tcf7l2)-Dependent Regulation of Protease and Cadherin Expression
As 3-O-sulfation of heparan sulfate has an important co-receptor function for numerous signal transduction pathways, the phenotypical changes due to heparan sulfate 3-O-sulfotransferase 2 (HS3ST2) reexpression were investigated in vitro using high and low invasive breast cancer cell lines. [Int J Cancer]
Identification of Novel Molecular Regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in Breast Cancer Cells by RNAi Screening
The underlying mechanisms that control TRAIL sensitivity in breast cancer cells are not well understood. Researchers performed small interfering RNA screens to identify molecular regulators of the TRAIL pathway in breast cancer cells. [Breast Cancer Res]
Flotillin Depletion Affects ErbB Protein Levels in Different Human Breast Cancer Cells
One of the main challenges in ErbB-targeting therapy is to inactivate signaling mediated by ErbB2-ErbB3 oncogenic receptor complexes. Investigators analyzed the regulatory role of flotillins on ErbB3 levels and ErbB2-ErbB3 complexes in SKBR3, MCF7 and MDA-MB-134-VI human breast cancer cells. [Biochim Biophys Acta]
Intratumoral Morphological Heterogeneity of Breast Cancer: Neoadjuvant Chemotherapy Efficiency and Multidrug Resistance Gene Expression
Investigators analyzed the association of neoadjuvant chemotherapy (NAC) response and pre- and post-NAC expression of the main multidrug resistance genes – ABCB1, ABCC1, ABCC5, ABCG1, and ABCG2, with the presence of different morphological structures in breast tumors. [Sci Rep]
Dual Inhibition of the Vascular Endothelial Growth Factor Pathway: A Phase I Trial Evaluating Bevacizumab and AZD2171 (Cediranib) in Patients with Advanced Solid Tumors
Cediranib was given orally daily for 21 days and bevacizumab intravenously every two weeks. Pharmacokinetics and correlates (nitric oxide synthase, nitrate oxide, and circulating tumor cells) were assessed. [Cancer]
Prognostic and Biological Significance of Proliferation and HER2 Expression in the Luminal Class of Breast Cancer
Investigators compared the proliferation status; assessed using KI67 labeling index, and HER2-expression in estrogen receptor positive breast cancer (BC) to assess their impact on the biological and clinical characteristics of luminal-BC. [Breast Cancer Res Treat]
The Intracrinology of Breast Cancer|
Some risk factors of breast cancer development, including obesity, have been postulated to interact with steroid metabolizing pathways. The authors summarize the current state of knowledge regarding intracrine metabolism including expression levels of various enzymes and receptors, focusing particularly upon the importance of the production of biologically potent steroids from circulating sulfated precursors such as DHEA-S. [J Steroid Biochem Mol Biol]
Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Have we missed an important article or publication in Mammary Cell News? Click here to submit!
Comments or Suggestions? Submit your feedback here.